CurifyLabs Reaches Significant Milestones in Market Expansion and Growth
As we reflect on 2023, we at CurifyLabs are proud to announce a year of success. Our journey this year has been marked by significant strides in product development, market entry, and overall growth.
Our Year of Expansion and Growth
Charlotta Topelius, our co-founder and CEO, shares her insights: “This year has been pivotal for us. We've worked hand in hand with our customers to refine our product, leading to its successful market launch this fall. Since then, we've seen a remarkable increase in revenue and market presence, establishing ourselves as leaders in mass customization solutions for medicines.”
Introducing Pharma Kit and the First Printable Pharmaceutical Inks
A highlight of our achievements in 2023 is the introduction of our Pharma Kit. This patented solution, combining innovative printable Pharma Inks with 3D printing technology and quality control, has set a new industry standard. We are proud to be the first company globally to offer GMP (Good Manufacturing Practice) produced Pharma Inks for personalized medicines.
Niklas Sandler, our co-founder and CTO, emphasizes the importance of customer collaboration: “Our approach has always been customer-centric. This year, we have worked with our technology in more than 30 pharmacies across eight European markets, leading to the development of our Pharma Kit solution that caters directly to the needs of pharmacists.”
Making Strides in Market Expansion
In 2023, we began collaborations with major European pharmacies and hospitals, including prestigious institutions like Charité Hospital in Germany and Lausanne University Hospital in Switzerland. Our operations now extend across Germany, France, Austria, Switzerland, Sweden, Estonia, Finland, and the Netherlands, and we've taken our first steps into the US market.
“We are thrilled to have earned the trust of prominent pharmacies and hospitals across Europe and excited about our new ventures in the US,” says Topelius.
Financial Success and Recognition
Following the launch of Pharma Kit in October 2023, we saw an immediate increase in our revenue. This early success is a testament to the product-market fit and the growing demand for automated compounding solutions.
Furthermore, we received a significant €2.5M grant from the EIC Accelerator program, a testament to our innovative contributions to the health tech sector in the EU. We also manage to aqcuire ISO 13485 for our quality management system.
The Rising Demand for Personalized Medicine
Personalized medicines represent the future of pharmaceutical care, and we're at the forefront of this revolution. Our automated solutions address the inefficiencies and risks associated with manual compounding, making personalized medicine more accessible and safe.
With the global compounding market projected to reach $18.2 billion by 2030, we are perfectly positioned to capture this growth.
Looking to the Future
As we move into the next year, we are excited to expand our business and introduce our solutions to new markets. Our ongoing product development efforts will include introducing new features and expanding our Pharma Ink portfolio, particularly focusing on oncology and pediatrics.
